UroGen (URGN) Q4 2025 Earnings Call Transcript

Motley Fool Transcribing, The Motley Fool

Mon, March 2, 2026 astatine 10:41 AM CST 34 min read

Image source: The Motley Fool.

Monday, March 2, 2026 astatine 10 a.m. ET

• President and Chief Executive Officer — Elizabeth A. Barrett

• Chief Medical Officer — Mark P. Schoenberg

• Chief Commercial Officer — David Lin

• Chief Financial Officer — Christopher Degnan

• Senior Director, Investor Relations — Vincent I. Perrone

Need a punctuation from a Motley Fool analyst? Email [email protected]

Vincent I. Perrone: Thank you. Good morning, everyone. Welcome to UroGen Pharma Ltd.'s full-year 2025 Financial Results and Business Update Conference Call. Earlier this morning, we issued 2 property releases, the archetypal providing an overview of the refinancing of our indebtedness installation with Pharma Advisors, and the 2nd providing an overview of our caller firm highlights and fiscal results for the 4th fourth and twelvemonth ended 12/31/2025. Both releases tin beryllium accessed connected the Investors information of our website astatine investors.urogen.com. Joining maine contiguous are Elizabeth A. Barrett, President and Chief Executive Officer; Mark P. Schoenberg, Chief Medical Officer; David Lin, Chief Commercial Officer; and Christopher Degnan, Chief Financial Officer. On today's call, we volition beryllium making definite forward-looking statements.

These whitethorn see statements regarding our ongoing commercialization activities related to Jelmyto and Zasturi, our ongoing and planned objective trials and nonclinical studies, the commercialized and objective improvement milestones, marketplace and gross opportunities, our commercialization and semipermanent maturation strategy and expectations, arsenic good arsenic anticipated data, regulatory filings and decisions, the imaginable benefits of our products and merchandise candidates, aboriginal R&D efforts and milestones, our firm goals, and 2026 fiscal guidance, among different things. These forward-looking statements are based connected existent accusation and expectations that are taxable to change. A statement of imaginable risks tin beryllium recovered successful our net property merchandise and latest SEC disclosure documents.

You are cautioned not to spot undue reliance connected these forward-looking statements and UroGen Pharma Ltd. disclaims immoderate work to update these statements. I volition present crook the telephone implicit to Elizabeth A. Barrett, Chief Executive Officer.

Elizabeth A. Barrett: Thanks, Vincent. Good morning, and convey you for joining america today. Our apical precedence is the commercialized motorboat of Zysturi successful recurrent, low-grade, intermediate-risk, non–muscle invasive bladder cancer, a pivotal measurement successful advancing our semipermanent maturation strategy. As we outlined successful our net merchandise this morning, we are encouraged by the aboriginal 2026 trajectory pursuing the imperishable J codification becoming effectual January 1. Zasturi gross successful 2025 was $15,800,000, reflecting aboriginal motorboat dynamics arsenic we enactment done emblematic reimbursement and operations steps indispensable to physique the instauration for broader adoption. With a imperishable J codification present successful place, a cardinal obstruction to adoption has been removed, facilitating much predictable diligent access.